Rocky Baker
Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
CD4-Positive T-Lymphocytes | 17 | 2022 | 959 | 2.710 |
Why?
| Autoantigens | 12 | 2022 | 396 | 2.560 |
Why?
| Diabetes Mellitus, Type 1 | 19 | 2022 | 3252 | 1.880 |
Why?
| Chromogranin A | 6 | 2021 | 39 | 1.650 |
Why?
| C-Peptide | 4 | 2021 | 138 | 1.450 |
Why?
| Insulin | 8 | 2022 | 2079 | 1.420 |
Why?
| Islet Amyloid Polypeptide | 4 | 2018 | 47 | 1.230 |
Why?
| Mice, Inbred NOD | 15 | 2022 | 555 | 0.850 |
Why?
| Islets of Langerhans | 6 | 2022 | 726 | 0.810 |
Why?
| Autoimmunity | 7 | 2022 | 813 | 0.790 |
Why?
| Epitopes, T-Lymphocyte | 3 | 2021 | 170 | 0.780 |
Why?
| Receptors, Antigen, T-Cell | 3 | 2021 | 615 | 0.680 |
Why?
| CD40 Antigens | 2 | 2012 | 82 | 0.670 |
Why?
| Peptides | 8 | 2022 | 848 | 0.590 |
Why?
| Recombination, Genetic | 1 | 2018 | 176 | 0.570 |
Why?
| Diabetes Mellitus, Experimental | 3 | 2021 | 160 | 0.560 |
Why?
| T-Lymphocytes | 2 | 2020 | 1737 | 0.480 |
Why?
| CD40 Ligand | 2 | 2012 | 39 | 0.470 |
Why?
| Peptide Fragments | 5 | 2022 | 666 | 0.470 |
Why?
| Lymphocyte Activation | 4 | 2018 | 1037 | 0.450 |
Why?
| Prediabetic State | 1 | 2013 | 219 | 0.360 |
Why?
| Epitopes | 4 | 2022 | 435 | 0.350 |
Why?
| Cells, Cultured | 7 | 2019 | 3886 | 0.330 |
Why?
| Mice | 16 | 2022 | 14869 | 0.330 |
Why?
| Adoptive Transfer | 3 | 2015 | 195 | 0.320 |
Why?
| Clone Cells | 3 | 2018 | 247 | 0.270 |
Why?
| Animals | 18 | 2022 | 31706 | 0.270 |
Why?
| Antigens, CD | 1 | 2008 | 442 | 0.260 |
Why?
| Specific Pathogen-Free Organisms | 2 | 2018 | 59 | 0.250 |
Why?
| Insulin-Secreting Cells | 3 | 2020 | 317 | 0.250 |
Why?
| Mice, SCID | 2 | 2018 | 314 | 0.240 |
Why?
| Mice, Knockout | 4 | 2021 | 2570 | 0.230 |
Why?
| HLA-DQ Antigens | 2 | 2021 | 174 | 0.200 |
Why?
| Flow Cytometry | 3 | 2015 | 1083 | 0.190 |
Why?
| Islets of Langerhans Transplantation | 1 | 2022 | 53 | 0.190 |
Why?
| K562 Cells | 1 | 2021 | 73 | 0.190 |
Why?
| Protein Array Analysis | 1 | 2021 | 56 | 0.180 |
Why?
| HLA-DRB1 Chains | 1 | 2020 | 98 | 0.170 |
Why?
| Graft Survival | 1 | 2022 | 446 | 0.170 |
Why?
| Nanoparticles | 2 | 2022 | 313 | 0.160 |
Why?
| Immunotherapy | 2 | 2021 | 474 | 0.160 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2012 | 2096 | 0.160 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 127 | 0.150 |
Why?
| Crosses, Genetic | 1 | 2018 | 139 | 0.150 |
Why?
| Immune System | 1 | 2019 | 172 | 0.150 |
Why?
| Leukocytes, Mononuclear | 1 | 2019 | 493 | 0.130 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2019 | 339 | 0.130 |
Why?
| Recombinant Fusion Proteins | 1 | 2019 | 616 | 0.130 |
Why?
| Mice, Inbred BALB C | 2 | 2016 | 1144 | 0.130 |
Why?
| Mice, Inbred C57BL | 2 | 2015 | 4694 | 0.120 |
Why?
| Microsatellite Repeats | 1 | 2015 | 136 | 0.120 |
Why?
| Autoimmune Diseases | 1 | 2018 | 382 | 0.120 |
Why?
| Disease Progression | 2 | 2019 | 2380 | 0.120 |
Why?
| Cell Proliferation | 2 | 2019 | 2187 | 0.110 |
Why?
| Female | 7 | 2022 | 59507 | 0.110 |
Why?
| CD4 Antigens | 1 | 2013 | 123 | 0.110 |
Why?
| Histocompatibility Antigens Class II | 1 | 2013 | 352 | 0.100 |
Why?
| Spleen | 1 | 2013 | 487 | 0.100 |
Why?
| Transduction, Genetic | 1 | 2012 | 113 | 0.100 |
Why?
| Pancreas | 1 | 2013 | 276 | 0.090 |
Why?
| Lymph Nodes | 1 | 2013 | 419 | 0.090 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2015 | 687 | 0.090 |
Why?
| B-Lymphocytes | 1 | 2015 | 766 | 0.090 |
Why?
| Microscopy, Fluorescence | 1 | 2012 | 396 | 0.090 |
Why?
| CD28 Antigens | 1 | 2008 | 47 | 0.080 |
Why?
| Humans | 8 | 2021 | 114686 | 0.080 |
Why?
| CTLA-4 Antigen | 1 | 2008 | 76 | 0.080 |
Why?
| Biomarkers | 1 | 2018 | 3408 | 0.080 |
Why?
| Signal Transduction | 2 | 2012 | 4513 | 0.070 |
Why?
| Male | 4 | 2021 | 55596 | 0.070 |
Why?
| Immune Tolerance | 2 | 2019 | 323 | 0.060 |
Why?
| Up-Regulation | 1 | 2008 | 808 | 0.060 |
Why?
| Young Adult | 1 | 2019 | 10469 | 0.060 |
Why?
| Adolescent | 2 | 2019 | 17844 | 0.050 |
Why?
| Cell Line | 1 | 2008 | 2637 | 0.050 |
Why?
| Cathepsin D | 1 | 2022 | 14 | 0.050 |
Why?
| Proteomics | 2 | 2022 | 836 | 0.050 |
Why?
| Insulin, Regular, Human | 1 | 2022 | 33 | 0.050 |
Why?
| Child | 2 | 2019 | 18414 | 0.050 |
Why?
| Transglutaminases | 2 | 2013 | 142 | 0.050 |
Why?
| Amino Acid Sequence | 2 | 2016 | 1982 | 0.050 |
Why?
| Antibodies, Monoclonal | 1 | 2008 | 1262 | 0.050 |
Why?
| Mice, Transgenic | 2 | 2021 | 1949 | 0.050 |
Why?
| Cytoprotection | 1 | 2021 | 51 | 0.050 |
Why?
| Drug Liberation | 1 | 2021 | 25 | 0.050 |
Why?
| Antigen Presentation | 1 | 2021 | 188 | 0.040 |
Why?
| Click Chemistry | 1 | 2021 | 48 | 0.040 |
Why?
| Solubility | 1 | 2021 | 223 | 0.040 |
Why?
| Remission Induction | 1 | 2021 | 233 | 0.040 |
Why?
| Adult | 2 | 2019 | 30550 | 0.040 |
Why?
| Cross Reactions | 1 | 2020 | 117 | 0.040 |
Why?
| Recurrence | 1 | 2022 | 935 | 0.040 |
Why?
| Animals, Genetically Modified | 1 | 2019 | 216 | 0.040 |
Why?
| Forkhead Transcription Factors | 1 | 2019 | 170 | 0.040 |
Why?
| Drug Delivery Systems | 1 | 2021 | 296 | 0.040 |
Why?
| Interferon-gamma | 1 | 2019 | 719 | 0.030 |
Why?
| Histocompatibility Testing | 1 | 2013 | 116 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2013 | 149 | 0.030 |
Why?
| Chromatography, Gel | 1 | 2012 | 122 | 0.030 |
Why?
| Molecular Sequence Data | 1 | 2016 | 2785 | 0.020 |
Why?
| Antigen-Presenting Cells | 1 | 2011 | 150 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2019 | 3535 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1421 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2011 | 633 | 0.020 |
Why?
| Treatment Outcome | 1 | 2021 | 9088 | 0.020 |
Why?
|
|
Baker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|